IMRT offers no significant benefit over CRT following prostatectomy

This article originally appeared here.
Share this content:
Intensity-Modulated No Better Than Conformal Radiotherapy
Intensity-Modulated No Better Than Conformal Radiotherapy

(HealthDay News) -- Intensity-modulated radiotherapy (IMRT) offers no significant benefit over conformal radiotherapy (CRT) following prostatectomy for prostate cancer, according to a study published online May 20 in JAMA Internal Medicine.

Gregg H. Goldin, M.D., from the University of North Carolina at Chapel Hill, and colleagues utilized data from the Surveillance, Epidemiology, and End Results-Medicare-linked database to identify patients diagnosed with prostate cancer who had received radiotherapy between 2002 and 2007, within three years after prostatectomy. Outcomes of 457 patients who received IMRT and 557 who received CRT were compared using claims data through 2009.

The researchers found that use of IMRT increased from 0 to 82.1 percent from 2000 to 2009. There were no significant differences in the rates of long-term gastrointestinal morbidity, urinary nonincontinent morbidity, urinary incontinence, or erectile dysfunction for men who received IMRT versus CRT. Additionally, subsequent treatment for recurrent disease was not significantly different between the groups.

"Given that IMRT is more expensive, its use for postprostatectomy radiotherapy may not be cost-effective compared with CRT, although formal analysis is needed," the authors write.

One author disclosed receiving salary support from unrestricted research grants from pharmaceutical companies.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs